Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2007-01-30
Target enrollment:
Participant gender:
Summary
To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience
erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .